A POTENIALLY YUUGE ADVANCE IN TREATING SCHIZOPHRENIA!!
Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psych... https://t.co/YrZIb8z1RY via @YahooFinance
An integrative framework for perceptual disturbances in psychosis | Nature Reviews Neuroscience. Linking transmitters and biased perception, hoping to understand how one goes from altered dopamine (and possibly other transmitters) to hearing voices https://t.co/L6p4l2NUpY
It was great to celebrate our Conte Center submission last night at Hudson Yards with views on the vessel. Great food, great friends and great hopes ๐!
Dynorphin and the Kappa Opioid Receptorโs Role in the Symptomatology of Schizophrenia: A Review of the Evidence - ScienceDirect: all you ever wanted to know about kappa and schizophrenia, now in Press in Biological Psychiatry!๐๐ https://t.co/qISkh3pDQh
@PhilCorlett1 @stonybrooku@GiorgiaMiche I enjoyed your talk! Always great insights and creative experimental designs! Looking forward to reading about you next steps!
@tomfolanmd The signal in Parkinson disease is very robust. Someone should take on the at risk state in Parkinson, this is where it would be most useful to develop as a bio marker.
Neuromelanin-sensitive MRI identified as a potential biomarker for psychosis, the paper is finally out in PNAS. For those interested in dopamine this is a validation of MRI sequence to image neuromelanin in the nigra, correlates to PET measures of dopamine https://t.co/Agcy7VTnA6